Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Shares of Vaxcyte (PCVX) rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine (PCV). The study was conducted on adults aged 50 years and older. Data from the study showed that the study participants who received VAX-31 achieved 'robust' immune responses for all 31 serotypes across all three dose levels (low, medium and high) in a six-month evaluation period. While the vaccine met or e ...